{
  "objCls" : "Guideline",
  "@id" : "https://api.pharmgkb.org/data/guideline/PA166104997",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104997",
  "name" : "CPIC Guideline for abacavir and HLA-B",
  "groups" : [ {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128752",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128752",
    "name" : "Absent",
    "annotations" : [ {
      "id" : 1445560529,
      "text" : "Low or reduced risk of abacavir hypersensitivity",
      "textHtml" : "<p>Low or reduced risk of abacavir hypersensitivity</p>",
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1445560765,
      "text" : "Very low risk of hypersensitivity (~94% of patients) in the absence of *57:01 alleles (reported as \"negative\" on a genotyping test)",
      "textHtml" : "<p>Very low risk of hypersensitivity (~94% of patients) in the absence of *57:01 alleles (reported as \"negative\" on a genotyping test)</p>",
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1445560530,
      "text" : "Use abacavir per standard dosing guidelines",
      "textHtml" : "<p>Use abacavir per standard dosing guidelines</p>",
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "HLA-B:Other/Other" ],
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930"
    }
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128753",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128753",
    "name" : "Present",
    "annotations" : [ {
      "id" : 1445561001,
      "text" : "Significantly increased risk of abacavir hypersensitivity",
      "textHtml" : "<p>Significantly increased risk of abacavir hypersensitivity</p>",
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1445561000,
      "text" : "High risk of hypersensitivity (~6% of patients) due to the presence of at least one *57:01 allele (reported as \"positive\" on a genotyping test)",
      "textHtml" : "<p>High risk of hypersensitivity (~6% of patients) due to the presence of at least one *57:01 allele (reported as \"positive\" on a genotyping test)</p>",
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1445561002,
      "text" : "Abacavir is not recommended",
      "textHtml" : "<p>Abacavir is not recommended</p>",
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "HLA-B:*57:01:01/*57:01:01", "HLA-B:*57:01:01/Other" ],
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930"
    }
  } ],
  "history" : [ {
    "id" : 1183699748,
    "date" : "2012-02-29T00:00:00-08:00",
    "type" : "update"
  }, {
    "id" : 1183704551,
    "date" : "2014-02-07T09:30:49.470-08:00",
    "type" : "approve"
  }, {
    "id" : 1183847536,
    "date" : "2014-02-28T00:00:00-08:00",
    "description" : "CPIC update to guidelines published",
    "type" : "update"
  } ],
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://api.pharmgkb.org/data/chemical/PA448004",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA448004",
    "name" : "abacavir",
    "version" : 6
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://api.pharmgkb.org/data/gene/PA35056",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA35056",
    "symbol" : "HLA-B",
    "name" : "major histocompatibility complex, class I, B",
    "version" : 38
  } ],
  "source" : "CPIC",
  "summary" : "In individuals with the HLA-B*57:01 variant allele (\"HLA-B*57:01-positive\"), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence.",
  "summaryHtml" : "<p>In individuals with the HLA-B*57:01 variant allele (\"HLA-B*57:01-positive\"), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence.</p>",
  "summaryMarkdown" : {
    "id" : 1447982036,
    "html" : "<p>In individuals with the HLA-B*57:01 variant allele (&quot;HLA-B*57:01-positive&quot;), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence.</p>\n",
    "internalLinks" : [ ],
    "markdown" : "In individuals with the HLA-B*57:01 variant allele (\"HLA-B*57:01-positive\"), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence.",
    "pmids" : [ ],
    "relatedObjects" : [ ],
    "rsids" : [ ]
  },
  "terms" : [ {"@id":"https://api.pharmgkb.org/data/ontologyTerm/cpicStatus/cpicStatus:1183847844","@context":"https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":1183847844,"resource":"CPIC Status","term":"A","termId":"cpicStatus:1183847844"} ],
  "text" : "h3. May 2014\r\n\r\n_Accepted article preview online 21 February 2014; Advance online publication 12 March 2014_\r\n\r\nThe [2014 update of CPIC guidelines|http://www.nature.com/clpt/journal/v95/n5/full/clpt201438a.html] regarding abacavir has been published in _Clinical Pharmacology and Therapeutics_. Literature published between April 2011-November 2013 was reviewed and there is *no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current*. \r\n* These guidelines are applicable to:\r\n** HIV Patients\r\n* Download and read:\r\n** [Clinical Pharmacogenetics Implementation Consortium Guidelines for _HLA-B_ Genotype and Abacavir Dosing: 2014 Update |^CPIC_HLAB_Abacavir_Update.pdf].\r\n** [2014 supplement|^CPIC_Abacavir_HLAB_Supplement_Update_MA.pdf].\r\n\r\nh3. April 2012\r\n\r\n_Advance online publication February 2012_\r\n* Download and read:\r\n** [Clinical Pharmacogenetics Implementation Consortium Guidelines for _HLA-B_ Genotype and Abacavir Dosing|^CPIC_HLAB-Abacavir.pdf] \r\n** [2012 supplement|^CPIC_HLAB-Abacavir_Supplemental_Material.pdf]. \r\n\r\nExcerpt from the abacavir dosing guidelines:\r\n\r\n{quote} We agree with others* that _HLA-B*57:01_ screening should be performed in all abacavir-naive individuals before initiation of abacavir-containing therapy (see Table 1 below); this is consistent with the recommendations of the FDA, the US Department of Health and Human Services, and the European Medicines Agency. In abacavir-naive individuals who are _HLA-B*57:01_-positive, abacavir is not recommended and should be considered only under exceptional circumstances when the potential benefit, based on resistance patterns and treatment history, outweighs the risk. {quote}\r\n\r\n*[PMID: 18826546, 19640227, 21174626, 21412232] [Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (PDF) |http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf]\r\n\r\n\r\nh3. Table 1: Recommended therapeutic use of abacavir based on _HLA-B_ genotype\r\n_Adapted from Tables 1 and 2 of the 2012 guideline manuscript._\r\n\r\n|| Likely phenotype || Genotypes || Examples of diplotypes || Implications for phenotypic measures   || Recommendations for abacavir therapy || Classification of recommendation for abacavir therapy ^a^ ||\r\n|Very low risk of hypersensitivity (constitutes ~94% ^b^ of patients) | Absence of _*57:01_ alleles (reported as \"negative\" on a genotyping test)| *X/*X ^c^|  Low or reduced risk of abacavir hypersensitivity  |  Use abacavir per standard dosing guidelines |  Strong |\r\n|High risk of hypersensitivity (~6% of patients) | Presence of at least one _*57:01_ allele (reported as \"positive\" on a genotyping test) | _*57:01_/*X ^c^ _*57:01/*57:01_ | Significantly increased risk of abacavir hypersensitivity| Abacavir is not recommended |  Strong |\r\n\r\n^a^ Rating scheme described in the [2012 Supplement|^ CPIC_HLAB-Abacavir_Supplemental_Material.pdf]\r\n\r\n^b^ See the [2012 Supplement|^ CPIC_HLAB-Abacavir_Supplemental_Material.pdf] for estimates of genotype frequencies among different ethnic/geographic groups\r\n\r\n^c^ *X = any _HLA-B_ genotype other than _*57:01_.\r\n_HLA-B_ = human leukocyte antigen B\r\n\r\n*Listen to an interview with the lead author:* [podcast|http://www.theaidsreader.com/display/article/1145619/2064707]",
  "textHtml" : "<h3 id=\"May2014\">May 2014</h3><p><em>Accepted article preview online 21 February 2014; Advance online publication 12 March 2014</em></p><p>The <a href=\"/redirect.jsp?p=http%3A%2F%2Fwww.nature.com%2Fclpt%2Fjournal%2Fv95%2Fn5%2Ffull%2Fclpt201438a.html\" target=\"offsite\">2014 update of CPIC guidelines</a> regarding abacavir has been published in <em>Clinical Pharmacology and Therapeutics</em>. Literature published between April 2011-November 2013 was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current</strong>. </p><ul><li>These guidelines are applicable to:<ul><li>HIV Patients</li></ul></li><li>Download and read:<ul><li><a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB_Abacavir_Update.pdf\">Clinical Pharmacogenetics Implementation Consortium Guidelines for <em>HLA-B</em> Genotype and Abacavir Dosing: 2014 Update</a>.</li><li><a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_Abacavir_HLAB_Supplement_Update_MA.pdf\">2014 supplement</a>.</li></ul></li></ul><h3 id=\"April2012\">April 2012</h3><p><em>Advance online publication February 2012</em></p><ul><li>Download and read:<ul><li><a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB-Abacavir.pdf\">Clinical Pharmacogenetics Implementation Consortium Guidelines for <em>HLA-B</em> Genotype and Abacavir Dosing</a> </li><li><a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB-Abacavir_Supplemental_Material.pdf\">2012 supplement</a>. </li></ul></li></ul><p>Excerpt from the abacavir dosing guidelines:</p><blockquote><p> We agree with others* that <em>HLA-B*57:01</em> screening should be performed in all abacavir-naive individuals before initiation of abacavir-containing therapy (see Table 1 below); this is consistent with the recommendations of the FDA, the US Department of Health and Human Services, and the European Medicines Agency. In abacavir-naive individuals who are <em>HLA-B*57:01</em>-positive, abacavir is not recommended and should be considered only under exceptional circumstances when the potential benefit, based on resistance patterns and treatment history, outweighs the risk. </p></blockquote><p>*[Articles:<a href=\"/pmid/18826546\">18826546</a>, <a href=\"/pmid/19640227\">19640227</a>, <a href=\"/pmid/21174626\">21174626</a>, <a href=\"/pmid/21412232\">21412232</a>] <a href=\"/redirect.jsp?p=http%3A%2F%2Fwww.aidsinfo.nih.gov%2FContentFiles%2FAdultandAdolescentGL.pdf\" target=\"offsite\">Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (PDF)</a></p><h3 id=\"Table1RecommendedtherapeuticuseofabacavirbasedonHLABgenotype\">Table 1: Recommended therapeutic use of abacavir based on <em>HLA-B</em> genotype</h3><p><em>Adapted from Tables 1 and 2 of the 2012 guideline manuscript.</em></p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Likely phenotype </th><th> Genotypes </th><th> Examples of diplotypes </th><th> Implications for phenotypic measures   </th><th> Recommendations for abacavir therapy </th><th> Classification of recommendation for abacavir therapy <sup>a</sup> </th></tr><tr><td>Very low risk of hypersensitivity (constitutes ~94% <sup>b</sup> of patients) </td><td> Absence of <em>*57:01</em> alleles (reported as \"negative\" on a genotyping test)</td><td> *X/*X <sup>c</sup></td><td>  Low or reduced risk of abacavir hypersensitivity  </td><td>  Use abacavir per standard dosing guidelines </td><td>  Strong </td></tr><tr><td>High risk of hypersensitivity (~6% of patients) </td><td> Presence of at least one <em>*57:01</em> allele (reported as \"positive\" on a genotyping test) </td><td> <em>*57:01</em>/*X <sup>c</sup> <em>*57:01/*57:01</em> </td><td> Significantly increased risk of abacavir hypersensitivity</td><td> Abacavir is not recommended </td><td>  Strong </td></tr></table><p><sup>a</sup> Rating scheme described in the <a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB-Abacavir_Supplemental_Material.pdf\">2012 Supplement</a></p><p><sup>b</sup> See the <a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB-Abacavir_Supplemental_Material.pdf\">2012 Supplement</a> for estimates of genotype frequencies among different ethnic/geographic groups</p><p><sup>c</sup> *X = any <em>HLA-B</em> genotype other than <em>*57:01</em>.<br/><em>HLA-B</em> = human leukocyte antigen B</p><p><strong>Listen to an interview with the lead author:</strong> <a href=\"/redirect.jsp?p=http%3A%2F%2Fwww.theaidsreader.com%2Fdisplay%2Farticle%2F1145619%2F2064707\" target=\"offsite\">podcast</a></p>",
  "textMarkdown" : {
    "id" : 1447982035,
    "html" : "<h3>May 2014</h3>\n<p><em>Accepted article preview online 21 February 2014; Advance online publication 12 March 2014</em></p>\n<p>The <a href=\"/redirect.jsp?p=http%3A%2F%2Fwww.nature.com%2Fclpt%2Fjournal%2Fv95%2Fn5%2Ffull%2Fclpt201438a.html\" target=\"offsite\">2014 update of CPIC guidelines</a> regarding abacavir has been published in <em>Clinical Pharmacology and Therapeutics</em>. Literature published between April 2011-November 2013 was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current</strong>.</p>\n<ul>\n<li>These guidelines are applicable to:\n<ul>\n<li>HIV Patients</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a href=\"/redirect.jsp?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fabacavir%2F2014%2F24561393.pdf\" target=\"offsite\">Clinical Pharmacogenetics Implementation Consortium Guidelines for <em>HLA-B</em> Genotype and Abacavir Dosing: 2014 Update </a>.</li>\n<li><a href=\"/redirect.jsp?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fabacavir%2F2014%2F24561393-supplement.pdf\" target=\"offsite\">2014 supplement</a>.</li>\n</ul>\n</li>\n</ul>\n<h3>April 2012</h3>\n<p><em>Advance online publication February 2012</em></p>\n<ul>\n<li>Download and read:\n<ul>\n<li><a href=\"/redirect.jsp?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fabacavir%2F2012%2F22378157.pdf\" target=\"offsite\">Clinical Pharmacogenetics Implementation Consortium Guidelines for <em>HLA-B</em> Genotype and Abacavir Dosing</a></li>\n<li><a href=\"/redirect.jsp?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fabacavir%2F2012%2F22378157-supplement.pdf\" target=\"offsite\">2012 supplement</a>.</li>\n</ul>\n</li>\n</ul>\n<p>Excerpt from the abacavir dosing guidelines:</p>\n<blockquote>\n<p>We agree with others* that <em>HLA-B*57:01</em> screening should be performed in all abacavir-naive individuals before initiation of abacavir-containing therapy (see Table 1 below); this is consistent with the recommendations of the FDA, the US Department of Health and Human Services, and the European Medicines Agency. In abacavir-naive individuals who are <em>HLA-B*57:01</em>-positive, abacavir is not recommended and should be considered only under exceptional circumstances when the potential benefit, based on resistance patterns and treatment history, outweighs the risk.</p>\n</blockquote>\n<p>*[Articles:<a href=\"/pmid/18826546\">18826546</a>, <a href=\"/pmid/19640227\">19640227</a>, <a href=\"/pmid/21174626\">21174626</a>, <a href=\"/pmid/21412232\">21412232</a>] <a href=\"/redirect.jsp?p=http%3A%2F%2Fwww.aidsinfo.nih.gov%2FContentFiles%2FAdultandAdolescentGL.pdf\" target=\"offsite\">Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (PDF) </a></p>\n<h3>Table 1: Recommended therapeutic use of abacavir based on <em>HLA-B</em> genotype</h3>\n<p><em>Adapted from Tables 1 and 2 of the 2012 guideline manuscript.</em></p>\n<table class=\"table table-striped table-condensed table-hover table-bordered\">\n<thead>\n<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications for phenotypic measures</th><th>Recommendations for abacavir therapy</th><th>Classification of recommendation for abacavir therapy <sup>a</sup></th></tr>\n</thead>\n<tbody>\n<tr><td>Very low risk of hypersensitivity (constitutes ~94% <sup>b</sup> of patients)</td><td>Absence of <em>*57:01</em> alleles (reported as &quot;negative&quot; on a genotyping test)</td><td>*X/*X <sup>c</sup></td><td>Low or reduced risk of abacavir hypersensitivity</td><td>Use abacavir per standard dosing guidelines</td><td>Strong</td></tr>\n<tr><td>High risk of hypersensitivity (~6% of patients)</td><td>Presence of at least one <em>*57:01</em> allele (reported as &quot;positive&quot; on a genotyping test)</td><td><em>*57:01</em>/*X <sup>c</sup> <em>*57:01/*57:01</em></td><td>Significantly increased risk of abacavir hypersensitivity</td><td>Abacavir is not recommended</td><td>Strong</td></tr>\n</tbody>\n</table>\n<p><sup>a</sup> Rating scheme described in the <a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB-Abacavir_Supplemental_Material.pdf\">2012 Supplement</a></p>\n<p><sup>b</sup> See the <a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB-Abacavir_Supplemental_Material.pdf\">2012 Supplement</a> for estimates of genotype frequencies among different ethnic/geographic groups</p>\n<p><sup>c</sup> *X = any <em>HLA-B</em> genotype other than <em>*57:01</em>.</p>\n<p><em>HLA-B</em> = human leukocyte antigen B</p>\n<p><strong>Listen to an interview with the lead author:</strong> <a href=\"/redirect.jsp?p=http%3A%2F%2Fwww.theaidsreader.com%2Fdisplay%2Farticle%2F1145619%2F2064707\" target=\"offsite\">podcast</a></p>\n",
    "internalLinks" : [ ],
    "markdown" : "## May 2014\r\n\r\n_Accepted article preview online 21 February 2014; Advance online publication 12 March 2014_\r\n\r\nThe [2014 update of CPIC guidelines](http://www.nature.com/clpt/journal/v95/n5/full/clpt201438a.html) regarding abacavir has been published in _Clinical Pharmacology and Therapeutics_. Literature published between April 2011-November 2013 was reviewed and there is __no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current__. \r\n- These guidelines are applicable to:\r\n  - HIV Patients\r\n- Download and read:\r\n  - [Clinical Pharmacogenetics Implementation Consortium Guidelines for _HLA-B_ Genotype and Abacavir Dosing: 2014 Update ](https://github.com/PharmGKB/cpic-guidelines/raw/master/abacavir/2014/24561393.pdf).\r\n  - [2014 supplement](https://github.com/PharmGKB/cpic-guidelines/raw/master/abacavir/2014/24561393-supplement.pdf).\r\n\r\n## April 2012\r\n\r\n_Advance online publication February 2012_\r\n- Download and read:\r\n  - [Clinical Pharmacogenetics Implementation Consortium Guidelines for _HLA-B_ Genotype and Abacavir Dosing](https://github.com/PharmGKB/cpic-guidelines/raw/master/abacavir/2012/22378157.pdf) \r\n  - [2012 supplement](https://github.com/PharmGKB/cpic-guidelines/raw/master/abacavir/2012/22378157-supplement.pdf). \r\n\r\nExcerpt from the abacavir dosing guidelines:\r\n\r\n> We agree with others* that _HLA-B*57:01_ screening should be performed in all abacavir-naive individuals before initiation of abacavir-containing therapy (see Table 1 below); this is consistent with the recommendations of the FDA, the US Department of Health and Human Services, and the European Medicines Agency. In abacavir-naive individuals who are _HLA-B*57:01_-positive, abacavir is not recommended and should be considered only under exceptional circumstances when the potential benefit, based on resistance patterns and treatment history, outweighs the risk.\r\n\r\n\r\n*[PMID: 18826546, 19640227, 21174626, 21412232] [Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (PDF) ](http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf)\r\n\r\n\r\n## Table 1: Recommended therapeutic use of abacavir based on _HLA-B_ genotype\r\n\r\n_Adapted from Tables 1 and 2 of the 2012 guideline manuscript._\r\n\r\n| Likely phenotype | Genotypes | Examples of diplotypes | Implications for phenotypic measures   | Recommendations for abacavir therapy | Classification of recommendation for abacavir therapy ^a^ |\r\n| --- | --- | --- | --- | --- | --- |\r\n|Very low risk of hypersensitivity (constitutes ~94% ^b^ of patients) | Absence of _*57:01_ alleles (reported as \"negative\" on a genotyping test)| *X/*X ^c^|  Low or reduced risk of abacavir hypersensitivity  |  Use abacavir per standard dosing guidelines |  Strong |\r\n|High risk of hypersensitivity (~6% of patients) | Presence of at least one _*57:01_ allele (reported as \"positive\" on a genotyping test) | _*57:01_/*X ^c^ _*57:01/*57:01_ | Significantly increased risk of abacavir hypersensitivity| Abacavir is not recommended |  Strong |\r\n\r\n^a^ Rating scheme described in the [2012 Supplement](^CPIC_HLAB-Abacavir_Supplemental_Material.pdf)\r\n\r\n^b^ See the [2012 Supplement](^CPIC_HLAB-Abacavir_Supplemental_Material.pdf) for estimates of genotype frequencies among different ethnic/geographic groups\r\n\r\n^c^ *X = any _HLA-B_ genotype other than _*57:01_.\r\n\r\n_HLA-B_ = human leukocyte antigen B\r\n\r\n__Listen to an interview with the lead author:__ [podcast](http://www.theaidsreader.com/display/article/1145619/2064707)",
    "pmids" : [ "21174626", "19640227", "21412232", "18826546" ],
    "relatedObjects" : [ ],
    "rsids" : [ ],
    "version" : 1
  },
  "variants" : [ ],
  "version" : 11,
  "xrefs" : [ {"@id":"https://api.pharmgkb.org/data/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/","@context":"https://www.pharmgkb.org/jsonld/crossReference.jsonld","id":1447983436,"resource":"Web Resource","xrefId":"https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/"} ]
}